Lymphoma Hub

In case you missed it! Does the addition of ibrutinib to immunochemotherapy improve outcomes in younger patients with mantle cell lymphoma with or without auto-HSCT? Check out our visual abstract of the phase III TRIANGLE trial here: https://loom.ly/trTLfF0 #lymsm #lymphoma #MedicalEducation

🚨 NEWS 🚨 Interim analysis of the phase III AMPLIFY (NCT03836261) trial shows significant improvement in PFS with fixed- duration acalabrutinib+venetoclax, with/without obinutuzumab, vs SoC chemoimmunotherapy in previously untreated #CLL Read more 👉 https://loom.ly/YRap9HY #lymsm #lymphoma #MedNews

⭐Lymphoma Hub spotlight: 6-year time to next treatment extrapolation curve for the GLOW study⭐ This analysis indicates a long estimated treatment-free period for previously untreated elderly and/or unfit patients with CLL who receive ibrutinib plus venetoclax. #lymphoma #lymsm

📝 Results of the placebo-controlled, phase III ECHO study presented at #EHA2024 showed that addition of acalabrutinib to bendamustine and rituximab significantly improved PFS in older patients with newly diagnosed MCL More news: LymphomaHub.com #lymphoma #MedNews #MedEd #lymsm

🚨NEWS 🚨 Iopofosine I 131 exceeds primary endpoint of major response rate in CLOVER WaM pivotal trial in patients with Waldenstrom’s macroglobulinemia. Read more here: https://loom.ly/ybBXPcw #lymsm #mednews

📝 Phase III results from the ECHO trial presented by @MichaelWangMD at #EHA2024 provide new insights for newly diagnosed older patients with #MCL; see: https://loom.ly/TDa35oM #lymphoma #MedNews #MedEd

During the Lymphoma Hub Steering Committee meeting, Astrid Pavlovsky, Fundaleu, Buenos Aires, AR, chaired a discussion on, Phase III GLOW trial: Ibrutinib plus venetoclax in previously untreated CLL/SLL. Check out these insights with the Lymphoma Hub Steering Committee: https://loom.ly/WelNNcQ #lymsm #Lymphoma

🚨 NEWS 🚨 Bexarotene receives a marketing authorization approval in Hong Kong for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma who progress after ≥1 prior systemic therapies. The approval is preceded by approval in Macau earlier this year. Read more here 👉 https://loom.ly/0r3RGDE #lymsm #lymphoma #MedNews

Results of the placebo-controlled, phase III ELECHON 3 study presented at #ASCO24 showed that brentuximab vedotin plus lenalidomide and rituximab significantly improved OS📝 This suggests that the triple combination could be a viable treatment option for patients with R/R DLBCL who have received ≥2 prior lines of systemic therapy. More news: lymphomahub.com #lymphoma #MedNews #MedEd

🚨 NEWS 🚨 The National Medical Products Administration (NMPA) of China has approved selinexor as a monotherapy for treating adult patients with R/R DLBCL, based on data from the registrational SEARCH study conducted in China in which selinexor achieved a pre-specified primary endpoint of ORR among 60 patients. 👉 https://loom.ly/tNP-160 #lymsm #lymphoma #MedNews